Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making
Panelists discuss how myelofibrosis management involves a combination of medications, supportive care, and potentially stem cell transplantation to alleviate symptoms, control disease progression, and improve quality of life.
Video Player is loading.
Now Viewing
EP: 1.Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making
EP: 2.Approved and Investigational Agents for Myelofibrosis
EP: 3.Disease Modification Strategies and Unmet Needs in Myelofibrosis
EP: 4.MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction
EP: 5.Disease- Modifying Biomarker Data in the MANIFEST-2 Study Investigating Pelabresib
EP: 6.Safety Profile of the Pelabresib and Ruxolitinib Combination in Myelofibrosis
EP: 7.Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders
Recent Videos
COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
Looking Ahead and Key Takeaways in EGFRm NSCLC
Assessing the Adverse Effect Profile of Ami-Laz in Comparison With Other Combination Therapies in EGFRm NSCLC
COCOON: Discussion of Clinical End Points and Dose Modifications
COCOON Baseline Characteristics
Related Content
